# SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

> **NCT02830542** · PHASE1 · COMPLETED · sponsor: **Seres Therapeutics, Inc.** · enrollment: 96 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** SER-262
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02830542
- **Lead sponsor:** Seres Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2018-05
- **Final completion:** 2018-08
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02830542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02830542, "SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02830542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*